牛黄降压制剂治疗原发性高血压的系统评价
该系统评价纳入12项随机对照试验共1651例原发性高血压患者,评估牛黄降压制剂(NHJYP)的疗效与安全性。结果显示,在采用中医诊断标准筛选的人群中,NHJYP单用或联合西药降压药可能改善血压和中医症状,但方法学质量低,证据不可靠。
要点
- 对采用中医诊断标准的高血压人群,NHJYP单用降压有效(RR=1.35)。
- NHJYP联合西药降压药可能降低血压并改善中医症状。
- 未报告严重不良事件,但整体证据质量低。
核心结论
- NHJYP对肝阳上亢、痰热壅盛证原发性高血压患者有一定益处,但证据不可靠。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed、Embase、Cochrane图书馆、CNKI、VIP、Sinomed和万方数据库至2015年6月。
- 纳入比较NHJYP或联合西药降压药与单用西药降压药的随机对照试验,共12项RCT、1651例。
主要发现
- NHJYP单用与西药降压药比较,对血压降低无显著效果;亚组分析显示,采用中医诊断标准人群RR=1.35(95%CI:1.17-1.56,P<0.0001),未采用者RR=0.96(95%CI:0.70-1.33,P=0.81)。
- 收缩压降低结果类似,但舒张压改善无显著差异。
- NHJYP联合西药降压药可能降低血压(RR=1.13,95%CI:1.03-1.24,P=0.01)并改善中医症状。
- 亚组分析提示采用中医诊断标准人群的血压降低效果显著。
- 未报告严重不良事件。
关键数值与推荐
- 主要结局为分类或连续血压,次要结局为中医证候。
临床怎么用
- 可考虑用于肝阳上亢、痰热壅盛证原发性高血压患者,尤其联合西药时。
- 需注意证据质量低,不应替代标准降压治疗。
局限性
- 纳入试验方法学质量低。
- 证据可靠性不足,需更严格设计试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Niuhuang Jiangya Preparation (NHJYP) is one of the most commonly used traditional Chinese patent medicines for essential hypertension (EH) in China. Our meta-analysis performed a systematic evaluation on the therapeutic efficacy and safety of NHJYP for EH. DESIGN: Systematic review and meta-analysis. METHODS: PubMed, Embase, the Cochrane library, CNKI,VIP, Sinomed, and Wanfang Database were searched up to June 2015. Randomized controlled trials (RCTs) comparing NHJYP or combined with western antihypertensive drugs (WAD) versus WAD were included. Quality of each trial was assessed according to the Cochrane Reviewers' Handbook 5. 1.0. Statistical software (RevMan 5.3) was used for data analysis. The primary outcome was categorical or continuous blood pressure, and the secondary outcome was Traditional Chinese Medicine (TCM) syndrome. RESULTS: 12 RCTs including 1651 cases were identified. The methodological quality of trials was low. Meta-analysis showed that, firstly, NHJYP used alone compared with WAD had no significant effect on BP reduction; however, subgroup analysis was used based on whether apply TCM diagnostic criteria in recruitment. It was suggested that, for population that applied TCM diagnostic criteria, RR=1.35,95% CI:1.17-1.56,P<0.0001; for population that didn't apply TCM diagnostic criteria, RR=0.96,95% CI:0.70-1.33,P=0.81.Reduction in systolic blood pressure (SBP) levels showed similar results. But there was no significant difference in improving diastolic blood pressure (DBP). Secondly, we found that NHJYP plus WAD probably lower BP (RR=1.13,95% CI:1.03-1.24,P=0.01)and improve TCM symptoms than WAD only. And subgroup analysis suggested significant BP reduction effect for population that applied TCM diagnostic. No serious adverse events were reported. CONCLUSIONS: Our review indicated that NHJYP has some beneficial effects in EH patients with liver-yang hyperactivity and abundant phlegm-heat syndrome. However, the evidence is not reliable enough. To produce definite evidence, more rigorously designed trials are needed.
引用
- Wang H, Liu C, Zhai J, et al. Niuhuang Jiangya Preparation (a traditional Chinese patent medicine) for essential hypertension: A systematic review. Complement Ther Med. 2017. PMID: 28434477. doi:10.1016/j.ctim.2017.02.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。